PALO ALTO, Calif., Jan. 04, 2018 -- Cardinal Analytx Solutions, a developer of advanced machine learning solutions for improving healthcare by predicting impending costs, today introduced its board of directors.
"Our board of directors brings significant experience both in healthcare and successfully growing entrepreneurial visions into market-changing companies," said Thomas McKinley, CEO of Cardinal Analytx. "We believe we have a significant opportunity with Cardinal Analytx to harness the power of artificial intelligence to improve healthcare and quality of life for patients, while reducing costs across the board."
The board of directors is comprised of:
- John Clarke – The chairman of Cardinal Analytx's board, Clarke also is a managing general partner of Cardinal Partners, where he has led investments in more than 100 growth companies with a cumulative market valuation exceeding $6 billion. He entered the venture industry in 1982 with DSV Partners, a pioneer venture capital fund. He led DSV’s healthcare and life sciences efforts, and was a co-founder and served as interim CEO of numerous successful companies, including Alkermes, Arris Pharmaceuticals, DNX and Cubist Pharmaceuticals. Clarke also led DSV's evolution into Cardinal Partners as co-founder.
- Kent Marquardt – A healthcare management executive with broad and deep experience, Marquardt is the CEO of Maverick Advisors LLC, which specializes in innovation and strategy with healthcare companies using analytics and customer engagement to attack inefficiencies in healthcare costs. Earlier in his career, he was executive vice president and CFO at Premera Blue Cross and held executive roles at American Dental Specialist Inc. and MedPartners Inc.
- Thomas McKinley – Currently serving as Cardinal Analytx's CEO, McKinley has a track record of helping entrepreneurs create significant and successful enterprises. In his role as a partner at Cardinal Partners, McKinley identifies early new market opportunities in health care and works with entrepreneurs, scientists, clinicians, engineers and inventors to build successful companies.
- Dr. Mark D. Smith – Currently a professor of Clinical Medicine at the University of California at San Francisco and visiting professor at the School of Public Health at the University of California at Berkeley, Dr. Smith is a nationally recognized health policy expert. He was elected to the Institute of Medicine where he chaired the IOM’s Committee on the Learning Healthcare System, which produced the widely-publicized 2012 report “Best Care at Lower Cost.” He also was a Menschel Senior Policy Fellow at the Harvard School of Public Health, and the former founding president of the California HealthCare Foundation.
- Elizabeth Spaulding – Head of Bain & Company’s global digital practice, Spaulding has significant experience with both public and private equity-owned businesses and advises clients on a range of issues related to digital disruption, including reinvention of the customer experience, marketing, innovation in operations including automation and predictive analytics, as well as helping develop new products and services. She founded and leads ADAPT, Bain's technical team of digital experts, and created the Bain Innovation Exchange that connects clients with venture capitalists, startups and major tech platforms.
“Cost blooms and tailored interventions are just the start of driving AI and machine learning solutions to managed care entities,” said Marquardt. “Cardinal Analytx offers the unique ability to analyze big data and apply machine learning to interventions, which will result in more opportunities and better outcomes for the patient and the risk bearing entities.”
Cardinal Analytx today also announced its advisory board, which brings together individuals who have decades of experience at leading healthcare plans, medical professionals and academics.
About Cardinal Analytx Solutions
Based in Palo Alto, Calif., Cardinal Analytx Solutions is an early-stage predictive analytics company that leverages machine learning and AI technology to identify potential high-expense health plan enrollees and provide targeted clinical recommendations designed to improve patient outcomes and contain costs. The company, which was spun out of Stanford University-affiliated StartX startup accelerator, is backed by Cardinal Partners, Premera Blue Cross and the Stanford-StartX Fund. Founded by two Stanford industry luminaries in medicine and biomedical data science, Drs. Arnie Milstein and Nigam Shah, Cardinal Analytx is committed to transforming patient lives by combining machine learning with clinical excellence. For more information, visit www.cardinalanalytx.com or email [email protected].
Media Contact:
Theresa Maloney
Cogenta Communications
415-225-5261
[email protected]


American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Washington Post Publisher Will Lewis Steps Down After Layoffs
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil
TSMC Eyes 3nm Chip Production in Japan with $17 Billion Kumamoto Investment 



